Nashbiotechs is a website covering the news on the non-alcoholic steatohepatitis disease, drug candidates, actors and future treatments!  We present a unique unbiased overview of the market. You can sign up to the newsletter here

Metabolon Logo 4-c w-tag

Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives. Metabolon’s expertise is accelerating research and product development across the pharmaceutical, biotechnology, consumer products, nutrition industries, as well as academic and government organizations. The company was founded in 2000.


Perspectum Diagnostics provides digital health solutions for liver and metabolic disease. LiverMultiScan, uses multiparametric MRI to provide quantitative analysis of liver tissue, measuring fat and correlates of iron and fibroinflammatory disease. There is a burgeoning interest in using LiverMultiScan in clinical practice to improve the patient pathway and experience, as research has shown that LiverMultiScan correlates with biopsy and clinical outcomes. As well as, MRCP+, which allows 3D visualisation and quantitative mapping of the pancreatobiliary system by enhancing conventional MRCP images.


The development of better medicine begins with better disease models. Unfortunately, current in vitro models poorly mimic the pathophysiology of fibrosis, leaving a major gap in compound screening and testing efforts in anti-fibrosis drug discovery. Xylyx Bio’s native, disease-specific extracellular matrix substrates allow drug candidates to be investigated in vitro in a disease-relevant environment, enabling cell models that are significantly more predictive of human pathophysiology. Xylyx Bio products comprise both the mechanical properties and complex ratios of ECM components specific and unique to each organ type and disease state and are available in a variety of 2D and 3D product formats to support high-throughput assays.


Accelerated Enrollment Solutions (AES) is the new standard in clinical trial productivity. Our innovative and integrated site and patient services secure the success of clinical trials by providing enrollment, timing, and budget certainty. AES offers sponsors and contract research organizations best-in-class site conduct and patient access solutions, which include engaging, recruiting and retaining patients in clinical studies via a global network of dedicated research sites.